But it wasn’t until 2011 that Bran­g­-wynne, Hyman and veteran cell biologist Tim Mitchison of Harvard Medical School clarified what nucleoli actually are: phase-separated liquidlike droplets.

When trastuzumab attaches to the HER2 receptor on cancer cells, it acts like a trojan horse, allowing emtansine to more effectively enter the cancer cells and kill them from within. The KATHERINE ...

According to precedent and due to his status, Yoon will probably be assigned a solitary cell, likely bigger and better appointed than the standard 6.56 square metre (71 square feet) single cells.

1 Department of Targeting Therapy and Immunology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China 2 Division of Thoracic Tumor Multimodality Treatment, Cancer Center, ...

The candidate, dubbed SIM0500, targets GPRC5D, BCMA and CD3 and is already in phase 1 trials for multiple myeloma in the U.S. and China. It’s not AbbVie’s first foray into T-cell engager ...

Bayer’s Parkinson’s disease cell therapy is moving into late-stage testing, with the upcoming trial set to be the first registrational phase 3 study for an investigational allogeneic cell ...

The reorganization begins and results with the basic configuration (known as pre-AC) in the early (E) phase of infection, but the sequence of developmental steps ... including an approach of targeting ...